CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision
pharmaphorum
JULY 25, 2022
It showed an overall response rate with Tecvayli of 63%, including 39% complete responses which is a remarkable result given that the patient recruited into the trial were very ill and heavily pre-treated. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.
Let's personalize your content